Lamy PJ - Search Results

1

Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression.

Lamy PJ, Verjat T, Servanton AC, Paye M, Leissner P, Mougin B. Lamy PJ, et al. Am J Clin Pathol. 2007 Sep;128(3):404-13. doi: 10.1309/K4JAF2NMD5EJU67Y. Am J Clin Pathol. 2007. PMID: 17709314

2

NASBA: a novel approach to assess hormonal receptors and ERBB2 status in breast cancer.

Lamy PJ, Verjat T, Paye M, Servanton AC, Grenier J, Leissner P, Mougin B. Lamy PJ, et al. Clin Chem Lab Med. 2006;44(1):3-12. doi: 10.1515/CCLM.2006.002. Clin Chem Lab Med. 2006. PMID: 16375577

3

Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women.

Desmetz C, Bascoul-Mollevi C, Rochaix P, Lamy PJ, Kramar A, Rouanet P, Maudelonde T, Mangé A, Solassol J. Desmetz C, et al. Among authors: lamy pj. Clin Cancer Res. 2009 Jul 15;15(14):4733-41. doi: 10.1158/1078-0432.CCR-08-3307. Epub 2009 Jul 7. Clin Cancer Res. 2009. PMID: 19584157

4

Worldwide variations in EGFR somatic mutations: a challenge for personalized medicine.

Lamy PJ, Jacot W. Lamy PJ, et al. Diagn Pathol. 2012 Feb 1;7:13. doi: 10.1186/1746-1596-7-13. Diagn Pathol. 2012. PMID: 22293080 Free PMC article.

5

Cathepsin D stimulates the activities of secreted plasminogen activators in the breast cancer acidic environment.

Maynadier M, Farnoud R, Lamy PJ, Laurent-Matha V, Garcia M, Rochefort H. Maynadier M, et al. Among authors: lamy pj. Int J Oncol. 2013 Nov;43(5):1683-90. doi: 10.3892/ijo.2013.2095. Epub 2013 Sep 10. Int J Oncol. 2013. PMID: 24026424

6

Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer.

Saadoun H, Lamy PJ, Thezenas S, Pouderoux S, Bibeau F, Montels F, Romieu G, Colombo PE, Gutowski M, Jacot W. Saadoun H, et al. Among authors: lamy pj. Future Oncol. 2014 Feb;10(2):195-209. doi: 10.2217/fon.13.177. Future Oncol. 2014. PMID: 24490606

7

Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2- pN0 early breast cancers.

Viala M, Alexandre M, Thezenas S, Lamy PJ, Maran-Gonzalez A, Gutowski M, Colombo PE, Romieu G, Jacot W, Guiu S. Viala M, et al. Among authors: lamy pj. Breast Cancer Res Treat. 2017 Oct;165(3):611-621. doi: 10.1007/s10549-017-4373-7. Epub 2017 Jul 6. Breast Cancer Res Treat. 2017. PMID: 28685212

8

Progesterone receptor quantification as a strong prognostic determinant in postmenopausal breast cancer women under tamoxifen therapy.

Lamy PJ, Pujol P, Thezenas S, Kramar A, Rouanet P, Guilleux F, Grenier J. Lamy PJ, et al. Breast Cancer Res Treat. 2002 Nov;76(1):65-71. doi: 10.1023/a:1020228620173. Breast Cancer Res Treat. 2002. PMID: 12408377

9

[HE4, a novel marker for epithelial ovarian cancer: evaluation of analytical performances].

Lamy PJ, Roques S, Viglianti C, Fabbro M, Montels F. Lamy PJ, et al. Ann Biol Clin (Paris). 2010 May-Jun;68(3):325-9. doi: 10.1684/abc.2010.0435. Ann Biol Clin (Paris). 2010. PMID: 20478777 Free article. French.

10

Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles.

Jacot W, Lopez-Crapez E, Thezenas S, Senal R, Fina F, Bibeau F, Romieu G, Lamy PJ. Jacot W, et al. Among authors: lamy pj. Breast Cancer Res. 2011;13(6):R133. doi: 10.1186/bcr3079. Epub 2011 Dec 22. Breast Cancer Res. 2011. PMID: 22192147 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

103 results

Search Page

Filters